Inicio
Resultado de la búsqueda
5 búsqueda de la palabra clave 'Neoplasms'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Giant forehead plasmacytoma as a growing lump in a patient with multiple myeloma / Yoel Korenfeld Kaplan ; Ricardo Andrés Cardona Quiceno
Título : Giant forehead plasmacytoma as a growing lump in a patient with multiple myeloma Tipo de documento : documento electrónico Autores : Yoel Korenfeld Kaplan, ; Ricardo Andrés Cardona Quiceno, Fecha de publicación : 2020 Títulos uniformes : Radiology Case Reports Idioma : Inglés (eng) Palabras clave : Multiple myeloma Plasmacytoma Forehead Neoplasms Plasma cell Resumen : Extramedullary plasmacytoma represents less than 5% of plasma cell malignancies, 85% corresponding to head and neck masses. Symptoms are related to compressive effects according to location, aesthetics issues and can be misleading associated with soft tissue disorders. In this case report, we discuss a 70-year-old woman who presented with a 3-month history of a growing painless forehead lump and confusion, for which she had an emergent simple head computed tomography scan. The images revealed a well-defined mass eroding the frontal bone with multiple lytic lesions that were also found along with long bones radiography. The mass biopsy showed a monomorphic plasmatic cell infiltrate, bone marrow studies confirmed the diagnosis of a light chain secreting multiple myeloma. Extramedullary plasmacytoma is a very unusual first presentation form of multiple myeloma and represents a clinical and radiological challenge. A systematic approach of lytic bone lesions along with the differential diagnosis of head masses are skills the clinician should develop to promptly recognize this condition considering further complications of delayed treatment. In this case, the histopathological confirmation allowed the patient to avoid neurosurgery and the early start of systemic chemotherapeutic treatment. Mención de responsabilidad : Adriana M Trejos T, María C Cuartas M, Yoel Korenfeld K y Ricardo Cardona Q Referencia : Radiol Case Rep. 2020 Oct 9;15(12):2589-2593. DOI (Digital Object Identifier) : 10.1016/j.radcr.2020.09.050 PMID : 33082903 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S1930-0433(20)30509-4 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5186 Giant forehead plasmacytoma as a growing lump in a patient with multiple myeloma [documento electrónico] / Yoel Korenfeld Kaplan, ; Ricardo Andrés Cardona Quiceno, . - 2020.
Obra : Radiology Case Reports
Idioma : Inglés (eng)
Palabras clave : Multiple myeloma Plasmacytoma Forehead Neoplasms Plasma cell Resumen : Extramedullary plasmacytoma represents less than 5% of plasma cell malignancies, 85% corresponding to head and neck masses. Symptoms are related to compressive effects according to location, aesthetics issues and can be misleading associated with soft tissue disorders. In this case report, we discuss a 70-year-old woman who presented with a 3-month history of a growing painless forehead lump and confusion, for which she had an emergent simple head computed tomography scan. The images revealed a well-defined mass eroding the frontal bone with multiple lytic lesions that were also found along with long bones radiography. The mass biopsy showed a monomorphic plasmatic cell infiltrate, bone marrow studies confirmed the diagnosis of a light chain secreting multiple myeloma. Extramedullary plasmacytoma is a very unusual first presentation form of multiple myeloma and represents a clinical and radiological challenge. A systematic approach of lytic bone lesions along with the differential diagnosis of head masses are skills the clinician should develop to promptly recognize this condition considering further complications of delayed treatment. In this case, the histopathological confirmation allowed the patient to avoid neurosurgery and the early start of systemic chemotherapeutic treatment. Mención de responsabilidad : Adriana M Trejos T, María C Cuartas M, Yoel Korenfeld K y Ricardo Cardona Q Referencia : Radiol Case Rep. 2020 Oct 9;15(12):2589-2593. DOI (Digital Object Identifier) : 10.1016/j.radcr.2020.09.050 PMID : 33082903 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S1930-0433(20)30509-4 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5186 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001632 AC-2020-126 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2020-126.pdfAdobe Acrobat PDF 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update / Luis Vicente Syro Moreno
Título : 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2018 Títulos uniformes : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : Chemotherapy neoplasms neuroendocrine tumors pituitary temozolomide Resumen : Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Leon D Ortiz, Kalman Kovacs Referencia : Endocr Relat Cancer. 2018 Aug;25(8):T159-T169. DOI (Digital Object Identifier) : 10.1530/ERC-18-0015 PMID : 29535142 En línea : https://erc.bioscientifica.com/view/journals/erc/25/8/ERC-18-0015.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4186 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update [documento electrónico] / Luis Vicente Syro Moreno, . - 2018.
Obra : Endocrine Related Cancer
Idioma : Inglés (eng)
Palabras clave : Chemotherapy neoplasms neuroendocrine tumors pituitary temozolomide Resumen : Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Leon D Ortiz, Kalman Kovacs Referencia : Endocr Relat Cancer. 2018 Aug;25(8):T159-T169. DOI (Digital Object Identifier) : 10.1530/ERC-18-0015 PMID : 29535142 En línea : https://erc.bioscientifica.com/view/journals/erc/25/8/ERC-18-0015.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4186 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000800 AC-2018-087 Archivo digital Producción Científica Artículos científicos Disponible
Título : DICER1 gene mutations in endocrine tumors Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2018 Títulos uniformes : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : DICER1 endocrine tumors mutation neoplasms pathology Resumen : In this review, the importance of the DICER1 gene in the function of endocrine cells is discussed. There is conclusive evidence that DICER1 mutations play a crucial role in the development, progression, cell proliferation, therapeutic responsiveness and behavior of several endocrine tumors. We review the literature of DICER1 gene mutations in thyroid, parathyroid, pituitary, pineal gland, endocrine pancreas, paragangliomas, medullary, adrenocortical, ovarian and testicular tumors. Although significant progress has been made during the last few years, much more work is needed to fully understand the significance of DICER1 mutations. Mención de responsabilidad : Michael Solarski, Fabio Rotondo, William D Foulkes, John R Priest, Luis V Syro, Henriett Butz, Michael D Cusimano, Kalman Kovacs Referencia : Endocr Relat Cancer. 2018 Mar;25(3):R197-R208. DOI (Digital Object Identifier) : 10.1530/ERC-17-0509 PMID : 29330195 En línea : https://erc.bioscientifica.com/view/journals/erc/25/3/ERC-17-0509.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4195 DICER1 gene mutations in endocrine tumors [documento electrónico] / Luis Vicente Syro Moreno, . - 2018.
Obra : Endocrine Related Cancer
Idioma : Inglés (eng)
Palabras clave : DICER1 endocrine tumors mutation neoplasms pathology Resumen : In this review, the importance of the DICER1 gene in the function of endocrine cells is discussed. There is conclusive evidence that DICER1 mutations play a crucial role in the development, progression, cell proliferation, therapeutic responsiveness and behavior of several endocrine tumors. We review the literature of DICER1 gene mutations in thyroid, parathyroid, pituitary, pineal gland, endocrine pancreas, paragangliomas, medullary, adrenocortical, ovarian and testicular tumors. Although significant progress has been made during the last few years, much more work is needed to fully understand the significance of DICER1 mutations. Mención de responsabilidad : Michael Solarski, Fabio Rotondo, William D Foulkes, John R Priest, Luis V Syro, Henriett Butz, Michael D Cusimano, Kalman Kovacs Referencia : Endocr Relat Cancer. 2018 Mar;25(3):R197-R208. DOI (Digital Object Identifier) : 10.1530/ERC-17-0509 PMID : 29330195 En línea : https://erc.bioscientifica.com/view/journals/erc/25/3/ERC-17-0509.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4195 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000809 AC-2018-096 Archivo digital Producción Científica Artículos científicos Disponible Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions / Luis Vicente Syro Moreno
Título : Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2018 Títulos uniformes : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : Alkylating agents chemotherapy DNA repair neoplasms neuroendocrine tumors O(6)-Methylguanine-DNA Methyltransferase pituitary temozolomide Resumen : Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Mauricio Camargo, Leon D Ortiz, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2018 Jun 15;9:318 DOI (Digital Object Identifier) : 10.3389/fendo.2018.00318 PMID : 29963012 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4163 Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions [documento electrónico] / Luis Vicente Syro Moreno, . - 2018.
Obra : Frontiers in Endocrinology
Idioma : Inglés (eng)
Palabras clave : Alkylating agents chemotherapy DNA repair neoplasms neuroendocrine tumors O(6)-Methylguanine-DNA Methyltransferase pituitary temozolomide Resumen : Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Mauricio Camargo, Leon D Ortiz, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2018 Jun 15;9:318 DOI (Digital Object Identifier) : 10.3389/fendo.2018.00318 PMID : 29963012 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4163 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000777 AC-2018-064 Archivo digital Producción Científica Artículos científicos Disponible Human kallikrein 10 expression in surgically removed human pituitary corticotroph adenomas: an immunohistochemical study / Luis Vicente Syro Moreno
Título : Human kallikrein 10 expression in surgically removed human pituitary corticotroph adenomas: an immunohistochemical study Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2015 Títulos uniformes : Applied Immunohistochemistry and Molecular Morphology Idioma : Inglés (eng) Palabras clave : Human kallkrein 10 immunohistochemistry neoplasms pituitary adenoma prognostic marker Resumen : Human kallikrein 10 (hk10), a secreted serine protease, was reported to function as a tumor suppressor. hK10 immunoexpression has been demonstrated in lactrotrophs and corticotrophs of the nontumorous human adenohypophysis. In the present study, for the first time we report hK10 immunoexpression in various surgically removed corticotroph adenoma subtypes. Specimens were fixed in formalin and embedded in paraffin. Immunostaining was performed using the streptavidin-biotin peroxidase complex method with an hK10-specific rabbit polyclonal antibody. Results showed that the endocrinologically active adrenocorticotropic hormone (ACTH)-producing pituitary tumors and the silent subtypes were immunopositve for hK10. Intensity of staining varied between the different subtypes. Intensity was lowest in the silent subtypes (silent corticotroph subtypes 1 and 2) compared with nontumorous human adenohypophysial corticotrophs, whereas the endocrinologically active subtypes (ACTH-secreting adenomas, corticotroph carcinomas, Crooke cell adenomas, Crooke cell carcinomas), showed the highest hK10 immunoexpression. Immunopositivity in the nuclei of the ACTH-secreting adenomas and carcinomas, as well as dual cytoplasmic and nuclear localization of hK10 in some of the secreting tumor types was an intriguing finding. Immunoexpression of hK10 in the ACTH-secreting tumors as well as in the Crooke cell tumors was significantly increased when compared with the nonfunctioning tumors and in the corticotrophs of nontumorous pituitaries. Mención de responsabilidad : Ashley Di Meo, Fabio Rotondo, Kalman Kovacs, Michael D Cusimano, Luis V Syro, Antonio Di Ieva, Eleftheros P Diamandis, George M Yousef Referencia : Appl Immunohistochem Mol Morphol. 2015 Jul;23(6):433-7. DOI (Digital Object Identifier) : 10.1097/PAI.0000000000000108 PMID : 25517869 En línea : https://journals.lww.com/appliedimmunohist/Abstract/2015/07000/Human_Kallikrein_ [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3875 Human kallikrein 10 expression in surgically removed human pituitary corticotroph adenomas: an immunohistochemical study [documento electrónico] / Luis Vicente Syro Moreno, . - 2015.
Obra : Applied Immunohistochemistry and Molecular Morphology
Idioma : Inglés (eng)
Palabras clave : Human kallkrein 10 immunohistochemistry neoplasms pituitary adenoma prognostic marker Resumen : Human kallikrein 10 (hk10), a secreted serine protease, was reported to function as a tumor suppressor. hK10 immunoexpression has been demonstrated in lactrotrophs and corticotrophs of the nontumorous human adenohypophysis. In the present study, for the first time we report hK10 immunoexpression in various surgically removed corticotroph adenoma subtypes. Specimens were fixed in formalin and embedded in paraffin. Immunostaining was performed using the streptavidin-biotin peroxidase complex method with an hK10-specific rabbit polyclonal antibody. Results showed that the endocrinologically active adrenocorticotropic hormone (ACTH)-producing pituitary tumors and the silent subtypes were immunopositve for hK10. Intensity of staining varied between the different subtypes. Intensity was lowest in the silent subtypes (silent corticotroph subtypes 1 and 2) compared with nontumorous human adenohypophysial corticotrophs, whereas the endocrinologically active subtypes (ACTH-secreting adenomas, corticotroph carcinomas, Crooke cell adenomas, Crooke cell carcinomas), showed the highest hK10 immunoexpression. Immunopositivity in the nuclei of the ACTH-secreting adenomas and carcinomas, as well as dual cytoplasmic and nuclear localization of hK10 in some of the secreting tumor types was an intriguing finding. Immunoexpression of hK10 in the ACTH-secreting tumors as well as in the Crooke cell tumors was significantly increased when compared with the nonfunctioning tumors and in the corticotrophs of nontumorous pituitaries. Mención de responsabilidad : Ashley Di Meo, Fabio Rotondo, Kalman Kovacs, Michael D Cusimano, Luis V Syro, Antonio Di Ieva, Eleftheros P Diamandis, George M Yousef Referencia : Appl Immunohistochem Mol Morphol. 2015 Jul;23(6):433-7. DOI (Digital Object Identifier) : 10.1097/PAI.0000000000000108 PMID : 25517869 En línea : https://journals.lww.com/appliedimmunohist/Abstract/2015/07000/Human_Kallikrein_ [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3875 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000455 AC-2015-008 Archivo digital Producción Científica Artículos científicos Disponible